Chemotherapy for breast cancer that has spread to the spinal fluid

This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.

This trial tests a chemotherapy drug called thiotepa, given through a small device placed under the scalp (Ommaya reservoir) that delivers the drug directly into the spinal fluid. It is for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord and who have stopped responding to certain targeted therapies.

This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.

This trial tests a combination treatment for cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). It uses an antibody given directly into the spinal fluid along with a chemotherapy drug, with the goal of targeting the cancer more effectively.

This trial tests a special type of radiation therapy that aims to treat cancer cells in the spinal fluid while protecting the brain's memory areas. It is for people with breast or lung cancer (or other solid tumors) that has spread to the fluid around the brain and spinal cord.

This trial tests if giving a higher dose of a third-generation EGFR-targeted pill (like osimertinib) along with chemotherapy injected into the spinal fluid can help people with advanced lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases) after standard doses stopped working. The goal is to see if this combination works better than just the higher dose of the pill alone.